Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

2.

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.

Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA Jr, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL, Varterasian M, Saha S, Zhou S.

Sci Transl Med. 2014 Aug 13;6(249):249ra111. doi: 10.1126/scitranslmed.3008982.

3.

Brain natriuretic peptide: potential adjunct for cardiac risk assessment and management during treatment with experimental anticancer agents.

Varterasian ML, Meyer MB, Pressler ML, Fingert HJ, LoRusso PM.

AAPS J. 2007;9(2):E115-6. doi: 10.1208/aapsj0902012. No abstract available.

4.

Cardiac safety, risk management, and oncology drug development.

Fingert HJ, Varterasian ML.

Clin Cancer Res. 2006 Jun 15;12(12):3646-7. No abstract available.

6.

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.

Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H.

J Clin Oncol. 2005 Aug 20;23(24):5597-604.

PMID:
16110019
7.

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB.

J Clin Oncol. 2005 Aug 10;23(23):5281-93. Epub 2005 Jul 11.

PMID:
16009947
8.

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB.

J Clin Oncol. 2004 Nov 15;22(22):4456-62. Epub 2004 Oct 13.

PMID:
15483017
9.

Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.

Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A.

Leuk Lymphoma. 2004 Oct;45(10):2079-84.

PMID:
15370253
10.

Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer.

Varterasian M, Fingert H, Agin M, Meyer M.

Clin Cancer Res. 2004 Sep 1;10(17):5967-8; author reply 5968-9. No abstract available.

11.

Baseline heart rate-corrected QT and eligibility for clinical trials in oncology.

Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, Zhou X, Healey D.

J Clin Oncol. 2003 Sep 1;21(17):3378-9. No abstract available.

PMID:
12947082
12.

Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A 3rd, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF.

J Clin Oncol. 2003 Apr 15;21(8):1498-504.

PMID:
12697873
13.

Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation.

Vaishampayan U, Karanes C, Du W, Varterasian M, al-Katib A.

Cancer Invest. 2002;20(3):303-10.

PMID:
12025224
14.

Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.

Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM.

Invest New Drugs. 2001;19(3):245-7.

PMID:
11561682
15.

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.

Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA Jr, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI.

J Clin Oncol. 2001 Feb 1;19(3):750-5.

PMID:
11157027
16.

Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database.

Varterasian ML, Graff JJ, Severson RK, Weiss L, al-Katib AM, Kalemkerian GP.

Cancer Invest. 2000;18(4):303-8.

PMID:
10808365
17.

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM.

Clin Cancer Res. 2000 Mar;6(3):825-8.

18.

Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.

Aref A, Narayan S, Tekyi-Mensah S, Varterasian M, Dan M, Eilender D, Karanes C, al-Katib A.

Radiat Oncol Investig. 1999;7(3):186-91.

PMID:
10406061
19.

Waldenström's macroglobulinemia in young African-American adults.

Ahmed S, Shurafa MS, Bishop CR, Varterasian M.

Am J Hematol. 1999 Mar;60(3):229-30.

20.

Advances in the biology and treatment of multiple myeloma.

Varterasian ML.

Curr Opin Oncol. 1999 Jan;11(1):3-8. Review.

PMID:
9914870
21.

Trisomy 6 as a primary karyotypic aberration in hematologic disorders.

Mohamed AN, Varterasian ML, Dobin SM, McConnell TS, Wolman SR, Rankin C, Willman CL, Head DR, Slovak ML.

Cancer Genet Cytogenet. 1998 Oct 15;106(2):152-5. Review.

PMID:
9797781
22.

Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.

Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A.

Clin Cancer Res. 1998 May;4(5):1337-43.

23.

Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.

Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM.

Clin Cancer Res. 1998 Feb;4(2):445-53.

24.

Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.

Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M, Al-Katib A.

Anticancer Drugs. 1998 Feb;9(2):149-56.

PMID:
9510501
25.

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM.

J Clin Oncol. 1998 Jan;16(1):56-62.

PMID:
9440723
26.

Tumor lysis syndrome in small cell carcinoma and other solid tumors.

Kalemkerian GP, Darwish B, Varterasian ML.

Am J Med. 1997 Nov;103(5):363-7. Review.

PMID:
9375703
27.

The heterogeneity of leukemia occurring after treatment for sarcoma.

Varterasian M, Zalupski M, Karanes C.

Am J Clin Oncol. 1997 Dec;20(6):585-6.

PMID:
9391546
28.

Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.

Varterasian M, Janakiraman N, Karanes C, Abella E, Uberti J, Dragovic J, Raman SB, al-Katib A, Du W, Silver SM, Adams PT, Sensenbrenner L, Ratanatharathorn V.

Am J Clin Oncol. 1997 Oct;20(5):462-6.

PMID:
9345328
29.
30.

A blood stem cell transplant in a person with concomitant Hodgkin disease and testicular carcinoma.

Varterasian ML, Aref A, Karanes C.

Bone Marrow Transplant. 1997 Apr;19(8):857-8.

31.

Secondary acute myelogenous leukemia following treatment with oral etoposide.

Katato K, Flaherty L, Varterasian M.

Am J Hematol. 1996 Sep;53(1):54-5. No abstract available.

32.

Acquired central diabetes insipidus complicating acute megakaryocytic leukemia.

Arabi Y, Varterasian M.

Am J Hematol. 1996 Jul;52(3):241. No abstract available.

33.

Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation.

Varterasian M, Ratanatharathorn V, Uberti JP, Karanes C, Abella E, Momin F, Kasten-Sportes C, Al-Katib A, Lum L, Heilbrun LK, et al.

Leuk Lymphoma. 1995 Dec;20(1-2):59-65.

PMID:
8750624
34.

BCR/ABL fusion located on chromosome 9 in chronic myeloid leukemia with a masked Ph chromosome.

Mohamed AN, Koppitch F, Varterasian M, Karanes C, Yao KL, Sarkar FH.

Genes Chromosomes Cancer. 1995 Jun;13(2):133-7.

PMID:
7542908
35.

Biologic and clinical advances in multiple myeloma.

Varterasian ML.

Oncology (Williston Park). 1995 May;9(5):417-24; discussion 429-30. Review.

36.

Bone marrow transplantation for multiple myeloma: the Wayne State experience.

Varterasian M, Ratanatharathorn V, Karanes C, Uberti J, Momin F, Abella E, Lum LG, Heilbrun LK, Sensenbrenner LL.

Bone Marrow Transplant. 1995 Feb;15(2):328-9. No abstract available.

PMID:
7773230
37.

Two new Drosophila genes related to human hematopoietic and neurogenic transcription factors.

Varterasian M, Lipkowitz S, Karsch-Mizrachi I, Paterson B, Kirsch I.

Cell Growth Differ. 1993 Nov;4(11):885-9.

38.

A comparative structural characterization of the human NSCL-1 and NSCL-2 genes. Two basic helix-loop-helix genes expressed in the developing nervous system.

Lipkowitz S, Göbel V, Varterasian ML, Nakahara K, Tchorz K, Kirsch IR.

J Biol Chem. 1992 Oct 15;267(29):21065-71.

39.

Quantitative spinal mineral analysis in children.

Gilsanz V, Varterasian M, Senac MO, Cann CE.

Ann Radiol (Paris). 1986;29(3-4):380-2. No abstract available.

PMID:
3752878

Supplemental Content

Loading ...
Support Center